Company: APXIF
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026339
Chunk: 361

Company: APx Acquisition Corp. I
Filing Date: 2025-03-31
Form: F-4/A
Chunk 361
---
 conditions, aging, physical performance, and long -termwellness. Most of our customers are between the ages of 25 to50, of which 50% are men, and 50% are women. Rewell’s word -of-mouthhas attracted select laboratories, nutrition centers and nutritionists interested in commercializing Rewell’s kits over -the -counter. These partners bring Rewell’s solutions to through their physical locations, where they can connect directly with their own health -consciousclients, offering a convenient way for customers to access our services. Since Rewell’s launch, we have collected user feedback and market insights to guide continuous improvement to our service to satisfy customers’ needs and maintain an experience that promotes word -of -mouth. Currently, Rewell is only available in Argentina. However, as a preparation to expand Rewell, we are currently obtaining microbiome samples from international markets to build a proprietary data base and offer Rewell in additional countries. Heritas Diagnostics Commercial Operations Heritas Diagnostics’ commercial operations are designed to deliver precise diagnostic information through clinical genetic tests, along with a range of treatment alternatives via detailed reports, aimed at enhancing patient care. This service is commercialized through clinical laboratories, which offer these tests to patients and healthcare providers. These laboratories are onboarded and receive continuous commercial and technical assessment to offer the genetic tests to their customer base. Clinical laboratories collect samples, ship them to our Argentine Wet -Labfor processing, and once results are complete, these are sent to the clinical laboratory to be sent to their customer. Once samples are processed, the Company generates reports with the results, which CIBIC then delivers to patients and physicians. For the services provided, the Company sets a price for each category of tests, which CIBIC pays per 184 test requested to Heritas Argentina. CIBIC then sells these tests to end consumers at a price it determines. Revenue generated from selling the tests and other genetics sequencing services is recognized at a point in time when the reports with the results of the tests are sent to CIBIC. Heritas Diagnostics conducts its marketing and sales through key partners, including CIBIC and Meyer. For more information, please refer to “ OmnigenicsAI Management’s Discussion and Analysis of Financial Condition and Results of Operations — Basis of Preparation and Significant Accounting Policies — Revenue recognition.” In respect of Heritas Diagnostics, marketing and sales is conducted by distribution partners. We support these by employing targeted marketing strategies to healthcare institutions, clinics, and medical professionals. These strategies include informative